{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T07:16:39Z","timestamp":1768979799264,"version":"3.49.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T00:00:00Z","timestamp":1768867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"UNC-Allucent PK\/PD Fellowship, Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill"},{"name":"Eshelman School of Pharmacy, University of North Carolina at Chapel Hill"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"DOI":"10.1007\/s00280-025-04862-w","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T03:10:59Z","timestamp":1768878659000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A pharmacokinetic-pharmacodynamic\/toxicodynamic model framework for PARP inhibitor combination therapy with DNA-damaging chemotherapeutics"],"prefix":"10.1007","volume":"96","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2608-5508","authenticated-orcid":false,"given":"Li","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2047-0577","authenticated-orcid":false,"given":"Ronald W.","family":"Bucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8099-9069","authenticated-orcid":false,"given":"Derek W.","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,20]]},"reference":[{"issue":"5","key":"4862_CR1","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"issue":"2","key":"4862_CR2","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","volume":"23","author":"FJ Groelly","year":"2023","unstructured":"Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M (2023) Targeting DNA damage response pathways in cancer. Nat Rev Cancer 23(2):78\u201394. https:\/\/doi.org\/10.1038\/s41568-022-00535-5","journal-title":"Nat Rev Cancer"},{"issue":"7035","key":"4862_CR3","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A (2005) Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434(7035):917\u2013921. https:\/\/doi.org\/10.1038\/nature03445","journal-title":"Nature"},{"issue":"9","key":"4862_CR4","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1158\/1535-7163.MCT-20-0992","volume":"20","author":"N Goel","year":"2021","unstructured":"Goel N, Foxall ME, Scalise CB, Wall JA, Arend RC (2021) Strategies in overcoming homologous recombination proficiency and PARP inhibitor resistance. Mol Cancer Ther 20(9):1542\u20131549. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0992","journal-title":"Mol Cancer Ther"},{"key":"4862_CR5","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.critrevonc.2016.10.010","volume":"108","author":"A Drean","year":"2016","unstructured":"Drean A, Lord CJ, Ashworth A (2016) PARP inhibitor combination therapy. Crit Rev Oncol Hematol 108:73\u201385. https:\/\/doi.org\/10.1016\/j.critrevonc.2016.10.010","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"4862_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrclinonc.2016.96","volume":"14","author":"JS Lopez","year":"2017","unstructured":"Lopez JS, Banerji U (2017) Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol 14(1):57\u201366. https:\/\/doi.org\/10.1038\/nrclinonc.2016.96","journal-title":"Nat Rev Clin Oncol"},{"key":"4862_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14225559","author":"HL Smith","year":"2022","unstructured":"Smith HL, Willmore E, Mukhopadhyay A, Drew Y, Curtin NJ (2022) Differences in durability of PARP inhibition by clinically approved PARP inhibitors: implications for combinations and scheduling. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14225559","journal-title":"Cancers (Basel)"},{"issue":"8","key":"4862_CR8","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-11-2425","volume":"18","author":"A Rajan","year":"2012","unstructured":"Rajan A, Carter CA, Kelly RJ, Gutierrez M, Kummar S, Szabo E, Yancey MA, Ji J, Mannargudi B, Woo S, Spencer S, Figg WD, Giaccone G (2012) A phase I combination study of Olaparib with cisplatin and gemcitabine in adults with solid tumors. Clin Cancer Res 18(8):2344\u20132351. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-2425","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4862_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s11060-015-1966-z","volume":"126","author":"HI Robins","year":"2016","unstructured":"Robins HI, Zhang P, Gilbert MR, Chakravarti A, de Groot JF, Grimm SA, Wang F, Lieberman FS, Krauze A, Trotti AM, Mohile N, Kee AY, Colman H, Cavaliere R, Kesari S, Chmura SJ, Mehta M (2016) A randomized phase I\/II study of ABT-888 in combination with Temozolomide in recurrent Temozolomide resistant glioblastoma: an NRG oncology RTOG group study. J Neurooncol 126(2):309\u2013316. https:\/\/doi.org\/10.1007\/s11060-015-1966-z","journal-title":"J Neurooncol"},{"issue":"4","key":"4862_CR10","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1007\/s10637-019-00857-6","volume":"38","author":"R van der Noll","year":"2020","unstructured":"van der Noll R, Jager A, Ang JE, Marchetti S, Mergui-Roelvink MWJ, de Bono JS, Lolkema MP, de Jonge MJA, van der Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, De Greve J, Schellens JHM (2020) Phase I study of intermittent olaparib capsule or tablet dosing in combination with carboplatin and paclitaxel (part 2). Invest New Drugs 38(4):1096\u20131107. https:\/\/doi.org\/10.1007\/s10637-019-00857-6","journal-title":"Invest New Drugs"},{"issue":"4","key":"4862_CR11","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1007\/s10637-019-00856-7","volume":"38","author":"R van der Noll","year":"2020","unstructured":"van der Noll R, Jager A, Ang JE, Marchetti S, Mergui-Roelvink MWJ, Lolkema MP, de Jonge MJA, van der Biessen DA, Brunetto AT, Arkenau HT, Tchakov I, Beijnen JH, de Bono JS, Schellens JHM (2020) Phase I study of continuous olaparib capsule dosing in combination with carboplatin and\/or paclitaxel (Part 1). Invest New Drugs 38(4):1117\u20131128. https:\/\/doi.org\/10.1007\/s10637-019-00856-7","journal-title":"Invest New Drugs"},{"issue":"8","key":"4862_CR12","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1007\/s11095-022-03288-w","volume":"39","author":"R Madabushi","year":"2022","unstructured":"Madabushi R, Seo P, Zhao L, Tegenge M, Zhu H (2022) Review: role of model-informed drug development approaches in the lifecycle of drug development and regulatory decision-making. Pharm Res 39(8):1669\u20131680. https:\/\/doi.org\/10.1007\/s11095-022-03288-w","journal-title":"Pharm Res"},{"key":"4862_CR13","unstructured":"FDA (2024) Optimizing the dosage of human prescription drugs and biological products for the treatment of oncologic diseases. Guidance for Industry"},{"issue":"6","key":"4862_CR14","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s10928-024-09940-9","volume":"51","author":"F Bachmann","year":"2024","unstructured":"Bachmann F, Koch G, Bauer RJ, Steffens B, Szinnai G, Pfister M, Schropp J (2024) Computing optimal drug dosing regarding efficacy and safety: the enhanced optidose method in NONMEM. J Pharmacokinet Pharmacodyn 51(6):919\u2013934. https:\/\/doi.org\/10.1007\/s10928-024-09940-9","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"22","key":"4862_CR15","doi-asserted-by":"publisher","first-page":"6633","DOI":"10.1158\/1078-0432.CCR-18-3882","volume":"25","author":"DC Bottino","year":"2019","unstructured":"Bottino DC, Patel M, Kadakia E, Zhou J, Patel C, Neuwirth R, Iartchouk N, Brake R, Venkatakrishnan K, Chakravarty A (2019) Dose optimization for anticancer drug combinations: maximizing therapeutic index via clinical exposure-toxicity\/preclinical exposure-efficacy modeling. Clin Cancer Res 25(22):6633\u20136643. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3882","journal-title":"Clin Cancer Res"},{"key":"4862_CR16","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12885-016-2308-z","volume":"16","author":"X Elharrar","year":"2016","unstructured":"Elharrar X, Barbolosi D, Ciccolini J, Meille C, Faivre C, Lacarelle B, Andre N, Barlesi F (2016) A phase Ia\/Ib clinical trial of metronomic chemotherapy based on a mathematical model of oral vinorelbine in metastatic non-small cell lung cancer and malignant pleural mesothelioma: rationale and study protocol. BMC Cancer 16:278. https:\/\/doi.org\/10.1186\/s12885-016-2308-z","journal-title":"BMC Cancer"},{"issue":"12","key":"4862_CR17","doi-asserted-by":"publisher","first-page":"6585","DOI":"10.21873\/anticanres.14683","volume":"40","author":"S Kobuchi","year":"2020","unstructured":"Kobuchi S, Ito Y (2020) Application of pharmacometrics of 5-fluorouracil to personalized medicine: a tool for predicting pharmacokinetic-pharmacodynamic\/toxicodynamic responses. Anticancer Res 40(12):6585\u20136597. https:\/\/doi.org\/10.21873\/anticanres.14683","journal-title":"Anticancer Res"},{"issue":"4","key":"4862_CR18","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00280-023-04625-5","volume":"93","author":"S Kobuchi","year":"2024","unstructured":"Kobuchi S, Morita A, Jonan S, Amagase K, Ito Y (2024) Translational PK-PD\/TD modeling of antitumor effects and peripheral neuropathy in gemcitabine and nab-paclitaxel chemotherapy from xenograft mice to patients for optimal dose and schedule. Cancer Chemother Pharmacol 93(4):365\u2013379. https:\/\/doi.org\/10.1007\/s00280-023-04625-5","journal-title":"Cancer Chemother Pharmacol"},{"key":"4862_CR19","doi-asserted-by":"publisher","first-page":"121584","DOI":"10.1016\/j.biomaterials.2022.121584","volume":"286","author":"S Kweon","year":"2022","unstructured":"Kweon S, Jeong YS, Chung SW, Lee H, Lee HK, Park SJ, Choi JU, Park J, Chung SJ, Byun Y (2022) Metronomic dose-finding approach in oral chemotherapy by experimentally-driven integrative mathematical modeling. Biomaterials 286:121584. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121584","journal-title":"Biomaterials"},{"key":"4862_CR20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jbi.2015.06.021","volume":"57","author":"J Zhu","year":"2015","unstructured":"Zhu J, Liu R, Jiang Z, Wang P, Yao Y, Shen Z (2015) Optimization of drug regimen in chemotherapy based on semi-mechanistic model for myelosuppression. J Biomed Inform 57:20\u201327. https:\/\/doi.org\/10.1016\/j.jbi.2015.06.021","journal-title":"J Biomed Inform"},{"issue":"1","key":"4862_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1215\/15228517-2008-078","volume":"11","author":"W Wick","year":"2009","unstructured":"Wick W, Platten M, Weller M (2009) New (alternative) Temozolomide regimens for the treatment of glioma. Neuro Oncol 11(1):69\u201379. https:\/\/doi.org\/10.1215\/15228517-2008-078","journal-title":"Neuro Oncol"},{"issue":"24","key":"4862_CR22","doi-asserted-by":"publisher","first-page":"4713","DOI":"10.1200\/JCO.2002.02.140","volume":"20","author":"LE Friberg","year":"2002","unstructured":"Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20(24):4713\u20134721. https:\/\/doi.org\/10.1200\/JCO.2002.02.140","journal-title":"J Clin Oncol"},{"issue":"1","key":"4862_CR23","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J (2020) PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer 19(1):107. https:\/\/doi.org\/10.1186\/s12943-020-01227-0","journal-title":"Mol Cancer"},{"key":"4862_CR24","doi-asserted-by":"publisher","first-page":"564601","DOI":"10.3389\/fcell.2020.564601","volume":"8","author":"M Rose","year":"2020","unstructured":"Rose M, Burgess JT, O\u2019Byrne K, Richard DJ, Bolderson E (2020) PARP inhibitors: clinical relevance, mechanisms of action and tumor resistance. Front Cell Dev Biol 8:564601. https:\/\/doi.org\/10.3389\/fcell.2020.564601","journal-title":"Front Cell Dev Biol"},{"issue":"12","key":"4862_CR25","doi-asserted-by":"publisher","first-page":"5609","DOI":"10.1002\/cam4.2471","volume":"8","author":"AH West","year":"2019","unstructured":"West AH, Knollman H, Dugan J, Hedeker D, Handorf EA, Nielsen SM, Bealin LC, Goldblatt LG, Willems H, Daly MB, Afghahi A, Olopade OI, Hulick PJ, Shagisultanova E, Huo D, Obeid E, Churpek JE (2019) Hematologic toxicity in BRCA1 and BRCA2 mutation carriers during chemotherapy: a retrospective matched cohort study. Cancer Med 8(12):5609\u20135618. https:\/\/doi.org\/10.1002\/cam4.2471","journal-title":"Cancer Med"},{"issue":"3","key":"4862_CR26","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205\u2013216. https:\/\/doi.org\/10.1093\/jnci\/92.3.205","journal-title":"J Natl Cancer Inst"},{"issue":"10","key":"4862_CR27","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1016\/j.clinthera.2016.08.010","volume":"38","author":"L Dirix","year":"2016","unstructured":"Dirix L, Swaisland H, Verheul HM, Rottey S, Leunen K, Jerusalem G, Rolfo C, Nielsen D, Molife LR, Kristeleit R, Vos-Geelen J, Mau-Sorensen M, Soetekouw P, van Herpen C, Fielding A, So K, Bannister W, Plummer R (2016) Effect of Itraconazole and Rifampin on the pharmacokinetics of Olaparib in patients with advanced solid tumors: results of two phase I open-label studies. Clin Ther 38(10):2286\u20132299. https:\/\/doi.org\/10.1016\/j.clinthera.2016.08.010","journal-title":"Clin Ther"},{"issue":"3","key":"4862_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s11523-016-0435-8","volume":"11","author":"J Mateo","year":"2016","unstructured":"Mateo J, Moreno V, Gupta A, Kaye SB, Dean E, Middleton MR, Friedlander M, Gourley C, Plummer R, Rustin G, Sessa C, Leunen K, Ledermann J, Swaisland H, Fielding A, Bannister W, Nicum S, Molife LR (2016) An adaptive study to determine the optimal dose of the tablet formulation of the PARP inhibitor Olaparib. Target Oncol 11(3):401\u2013415. https:\/\/doi.org\/10.1007\/s11523-016-0435-8","journal-title":"Target Oncol"},{"issue":"4","key":"4862_CR29","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00280-015-2836-2","volume":"76","author":"R Plummer","year":"2015","unstructured":"Plummer R, Swaisland H, Leunen K, van Herpen CM, Jerusalem G, De Greve J, Lolkema MP, Soetekouw P, Mau-Sorensen M, Nielsen D, Spicer J, Fielding A, So K, Bannister W, Molife LR (2015) Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. Cancer Chemother Pharmacol 76(4):723\u2013729. https:\/\/doi.org\/10.1007\/s00280-015-2836-2","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"4862_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2014.9","volume":"3","author":"A Ballesta","year":"2014","unstructured":"Ballesta A, Zhou Q, Zhang X, Lv H, Gallo JM (2014) Multiscale design of cell-type-specific pharmacokinetic\/pharmacodynamic models for personalized medicine: application to temozolomide in brain tumors. CPT Pharmacometrics Syst Pharmacol 3(4):e112. https:\/\/doi.org\/10.1038\/psp.2014.9","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"4862_CR31","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/sj.bjc.6690802","volume":"81","author":"M Brada","year":"1999","unstructured":"Brada M, Judson I, Beale P, Moore S, Reidenberg P, Statkevich P, Dugan M, Batra V, Cutler D (1999) Phase I dose-escalation and pharmacokinetic study of Temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 81(6):1022\u20131030. https:\/\/doi.org\/10.1038\/sj.bjc.6690802","journal-title":"Br J Cancer"},{"issue":"8","key":"4862_CR32","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1200\/JCO.1999.17.8.2604","volume":"17","author":"LA Hammond","year":"1999","unstructured":"Hammond LA, Eckardt JR, Baker SD, Eckhardt SG, Dugan M, Forral K, Reidenberg P, Statkevich P, Weiss GR, Rinaldi DA, Von Hoff DD, Rowinsky EK (1999) Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 17(8):2604\u20132613. https:\/\/doi.org\/10.1200\/JCO.1999.17.8.2604","journal-title":"J Clin Oncol"},{"issue":"2","key":"4862_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa0900212","volume":"361","author":"PC Fong","year":"2009","unstructured":"Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O\u2019Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS (2009) Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123\u2013134. https:\/\/doi.org\/10.1056\/NEJMoa0900212","journal-title":"N Engl J Med"},{"key":"4862_CR34","unstructured":"AstraZeneca Lynparza (olaparib) [package insert]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/208558s031lbl.pdf"},{"key":"4862_CR35","unstructured":"Lynparza (olaparib) Clinical Pharmacology Review. U.S. Center for Drug Evaluation and Research. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/206162Orig1s000ClinPharmR.pdf"},{"key":"4862_CR36","unstructured":"Merck Temodar (temozolomide) [package insert]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/022277s017_018_019lbl.pdf"},{"issue":"7","key":"4862_CR37","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.neo.2018.05.001","volume":"20","author":"MC de Gooijer","year":"2018","unstructured":"de Gooijer MC, de Vries NA, Buckle T, Buil LCM, Beijnen JH, Boogerd W, van Tellingen O (2018) Improved brain penetration and antitumor efficacy of Temozolomide by inhibition of ABCB1 and ABCG2. Neoplasia 20(7):710\u2013720. https:\/\/doi.org\/10.1016\/j.neo.2018.05.001","journal-title":"Neoplasia"},{"issue":"11","key":"4862_CR38","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1158\/1541-7786.MCR-15-0191-T","volume":"13","author":"TA Hopkins","year":"2015","unstructured":"Hopkins TA, Shi Y, Rodriguez LE, Solomon LR, Donawho CK, DiGiammarino EL, Panchal SC, Wilsbacher JL, Gao W, Olson AM, Stolarik DF, Osterling DJ, Johnson EF, Maag D (2015) Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors. Mol Cancer Res 13(11):1465\u20131477. https:\/\/doi.org\/10.1158\/1541-7786.MCR-15-0191-T","journal-title":"Mol Cancer Res"},{"issue":"13","key":"4862_CR39","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1111\/febs.15568","volume":"288","author":"N Zilio","year":"2021","unstructured":"Zilio N, Ulrich HD (2021) Exploring the ssbreakome: genome-wide mapping of DNA single-strand breaks by next-generation sequencing. FEBS J 288(13):3948\u20133961. https:\/\/doi.org\/10.1111\/febs.15568","journal-title":"FEBS J"},{"issue":"22","key":"4862_CR40","doi-asserted-by":"publisher","first-page":"12871","DOI":"10.1073\/pnas.2135498100","volume":"100","author":"MM Vilenchik","year":"2003","unstructured":"Vilenchik MM, Knudson AG (2003) Endogenous DNA double-strand breaks: production, fidelity of repair, and induction of cancer. Proc Natl Acad Sci U S A 100(22):12871\u201312876. https:\/\/doi.org\/10.1073\/pnas.2135498100","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"4862_CR41","doi-asserted-by":"publisher","first-page":"7357","DOI":"10.1158\/1078-0432.CCR-07-0689","volume":"13","author":"MM Tilanus-Linthorst","year":"2007","unstructured":"Tilanus-Linthorst MM, Obdeijn IM, Hop WC, Causer PA, Leach MO, Warner E, Pointon L, Hill K, Klijn JG, Warren RM, Gilbert FJ (2007) BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, united Kingdom, and Canadian magnetic resonance imaging screening trials. Clin Cancer Res 13(24):7357\u20137362. https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0689","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4862_CR42","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/BF01273744","volume":"1","author":"SI Rubinow","year":"1975","unstructured":"Rubinow SI, Lebowitz JL (1975) A mathematical model of neutrophil production and control in normal man. J Math Biol 1(3):187\u2013225. https:\/\/doi.org\/10.1007\/BF01273744","journal-title":"J Math Biol"},{"issue":"4","key":"4862_CR43","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1189\/jlb.1112571","volume":"94","author":"T Tak","year":"2013","unstructured":"Tak T, Tesselaar K, Pillay J, Borghans JA, Koenderman L (2013) What\u2019s your age again? Determination of human neutrophil half-lives revisited. J Leukoc Biol 94(4):595\u2013601. https:\/\/doi.org\/10.1189\/jlb.1112571","journal-title":"J Leukoc Biol"},{"issue":"1","key":"4862_CR44","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/0014-4827(70)90268-5","volume":"61","author":"IT Boll","year":"1970","unstructured":"Boll IT, Fuchs G (1970) A kinetic model of granulocytopoiesis. Exp Cell Res 61(1):147\u2013152. https:\/\/doi.org\/10.1016\/0014-4827(70)90268-5","journal-title":"Exp Cell Res"},{"issue":"16","key":"4862_CR45","doi-asserted-by":"publisher","first-page":"7589","DOI":"10.1093\/nar\/gkt556","volume":"41","author":"A Schipler","year":"2013","unstructured":"Schipler A, Iliakis G (2013) DNA double-strand-break complexity levels and their possible contributions to the probability for error-prone processing and repair pathway choice. Nucleic Acids Res 41(16):7589\u20137605. https:\/\/doi.org\/10.1093\/nar\/gkt556","journal-title":"Nucleic Acids Res"},{"issue":"6","key":"4862_CR46","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1038\/emboj.2011.27","volume":"30","author":"A Shibata","year":"2011","unstructured":"Shibata A, Conrad S, Birraux J, Geuting V, Barton O, Ismail A, Kakarougkas A, Meek K, Taucher-Scholz G, Lobrich M, Jeggo PA (2011) Factors determining DNA double-strand break repair pathway choice in G2 phase. EMBO J 30(6):1079\u20131092. https:\/\/doi.org\/10.1038\/emboj.2011.27","journal-title":"EMBO J"},{"issue":"4","key":"4862_CR47","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1158\/0008-5472.CAN-16-2983","volume":"77","author":"A Thomas","year":"2017","unstructured":"Thomas A, Tanaka M, Trepel J, Reinhold WC, Rajapakse VN, Pommier Y (2017) Temozolomide in the era of precision medicine. Cancer Res 77(4):823\u2013826. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2983","journal-title":"Cancer Res"},{"issue":"25","key":"4862_CR48","doi-asserted-by":"publisher","first-page":"4189","DOI":"10.1200\/JCO.2007.11.5964","volume":"26","author":"ME Hegi","year":"2008","unstructured":"Hegi ME, Liu L, Herman GJ, Stupp R, Wick W, Weller M, Mehta MP, Gilbert MR (2008) Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. J Clin Oncol 26(25):4189\u20134199. https:\/\/doi.org\/10.1200\/JCO.2007.11.5964","journal-title":"J Clin Oncol"},{"issue":"1","key":"4862_CR49","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1592\/phco.24.1.16.34800","volume":"24","author":"MA Rudek","year":"2004","unstructured":"Rudek MA, Donehower RC, Statkevich P, Batra VK, Cutler DL, Baker SD (2004) Temozolomide in patients with advanced cancer: phase I and pharmacokinetic study. Pharmacotherapy 24(1):16\u201325. https:\/\/doi.org\/10.1592\/phco.24.1.16.34800","journal-title":"Pharmacotherapy"},{"issue":"9","key":"4862_CR50","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(11)70214-5","volume":"12","author":"KA Gelmon","year":"2011","unstructured":"Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B, Yerushalmi R, Macpherson E, Carmichael J, Oza A (2011) Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 12(9):852\u2013861. https:\/\/doi.org\/10.1016\/S1470-2045(11)70214-5","journal-title":"Lancet Oncol"},{"issue":"6","key":"4862_CR51","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1056\/NEJMoa1706450","volume":"377","author":"M Robson","year":"2017","unstructured":"Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P (2017) Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 377(6):523\u2013533. https:\/\/doi.org\/10.1056\/NEJMoa1706450","journal-title":"N Engl J Med"},{"issue":"6","key":"4862_CR52","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s002800050691","volume":"40","author":"M Bower","year":"1997","unstructured":"Bower M, Newlands ES, Bleehen NM, Brada M, Begent RJ, Calvert H, Colquhoun I, Lewis P, Brampton MH (1997) Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 40(6):484\u2013488. https:\/\/doi.org\/10.1007\/s002800050691","journal-title":"Cancer Chemother Pharmacol"},{"issue":"13","key":"4862_CR53","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1016\/s0959-8049(96)00258-4","volume":"32A","author":"ES Newlands","year":"1996","unstructured":"Newlands ES, O\u2019Reilly SM, Glaser MG, Bower M, Evans H, Brock C, Brampton MH, Colquhoun I, Lewis P, Rice-Edwards JM, Illingworth RD, Richards PG (1996) The Charing cross hospital experience with temozolomide in patients with gliomas. Eur J Cancer 32A(13):2236\u20132241. https:\/\/doi.org\/10.1016\/s0959-8049(96)00258-4","journal-title":"Eur J Cancer"},{"issue":"4","key":"4862_CR54","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1208\/s12248-025-01088-9","volume":"27","author":"RW Bucher","year":"2025","unstructured":"Bucher RW, Graves LM, Bartlett DW (2025) Dose optimization of ClpP agonists using an in vitro microfluidic perfusion platform and in silico pharmacokinetic-pharmacodynamic modeling. AAPS J 27(4):109. https:\/\/doi.org\/10.1208\/s12248-025-01088-9","journal-title":"AAPS J"},{"issue":"2","key":"4862_CR55","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1158\/1078-0432.CCR-05-2543","volume":"12","author":"L Liu","year":"2006","unstructured":"Liu L, Gerson SL (2006) Targeted modulation of MGMT: clinical implications. Clin Cancer Res 12(2):328\u2013331. https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-2543","journal-title":"Clin Cancer Res"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04862-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-025-04862-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-025-04862-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T15:22:04Z","timestamp":1768922524000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-025-04862-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4862"],"URL":"https:\/\/doi.org\/10.1007\/s00280-025-04862-w","relation":{},"ISSN":["1432-0843"],"issn-type":[{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"L.C., R.W.B., and D.W.B. declare no conflicts of interest for the work presented in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"11"}}